SYS-CON MEDIA Authors: Unitiv Blog, Mark R. Hinkle, Glenn Rossman, Kevin Benedict, Jason Bloomberg

News Feed Item

Concise Analysis of the Chinese Pharmaceutical Equipment Industry

DUBLIN, March 18, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/rs4wkl/china) has announced the addition of the "Concise Analysis of the Chinese Pharmaceutical Equipment Industry" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total profit of China's pharmaceutical equipment industry both have increased significantly, and the revenue achieved a year-on-year growth rate of 51.5%, 28.2% and 26% in 2010-2012 respectively.

However, restricted by the actual progress of new GMP certification and market capacity, the revenue growth of China's pharmaceutical equipment industry will slow down in 2013-2016, probably at an annual average growth rate of 20% or so, and the revenue is expected to reach RMB 53.22 billion in 2016. 

Due to a wide range of pharmaceutical equipment product categories and a customized business model generally adopted by enterprises, there is no one or a few pharmaceutical equipment companies capable of controlling the entire market, the industry concentration is low, the majority of enterprises are small and medium-sized, and the market concentration is low (20%=CR8<40%).

Shinva Medical Instrument Co., Ltd. is a leading sterilization equipment company in China. Its revenue from medical equipment (including pharmaceutical equipment) was RMB 2.408 billion in 2012 and RMB 1.524 billion in the first half of 2013. According to the statistics of China Association for Pharmaceutical Equipment, Shinva sold 10,048 units of sterilization equipment in 2012 and 7,873 units in the first 11 months of 2013, accounting for 86.8% and 84.3% of the total sales volume respectively. 

Shanghai Tofflon Science and Technology Co., Ltd. is the leader in China's freeze-drying system industry, and realized revenue of RMB 822 million in 2012, accounting for 3.3% of China's pharmaceutical equipment market; in China's freeze-dryer market, it occupied a market share of 50-60% by sales in 2012 and 2013. 

Truking Technology Limited is a major supplier of liquid injection pharmaceutical equipment in China, its revenue in 2012 was RMB 589 million, occupying 2.3% of China's pharmaceutical equipment market; in 2012, it accounted for 29.2% of the infusion device market by sales volume. Hunan China Sun Pharmaceutical Machinery Co., Ltd. is also an important supplier of injection pharmaceutical equipment in China, its revenue in 2012 was RMB 365 million, holding 1.4% of China's pharmaceutical equipment market; in 2012, it contributed 19.1% of the sales volume in the infusion device market. 


Key Topics Covered: 

1. Overview of Pharmaceutical Equipment Industry 

2. Overview of Chinese Pharmaceutical Equipment Industry 

3. Development Environment of China Pharmaceutical Equipment Industry 

4. China Pharmaceutical Equipment Industry Development Forecast 

5. Major Enterprises of China Pharmaceutical Equipment Industry


Companies Mentioned:

  • Beijing Double-Crane Pharmaceutical Equipment
  • Harbin Nano Pharmaceutical & Chemical Equipment
  • Hunan China Sun Pharmaceutical Machinery
  • Jiangsu Saideli Pharmaceutical Machine
  • Shanghai Far-East Pharmaceutical Machinery
  • Shanghai Tofflon Science and Technology
  • Shinva Medical Instrument
  • Truking Technology Limited
  • Wenzhou Yaguang Machinery Manufacturing
  • Zhejiang Hualian Pharmaceutical Machinery

For more information visit http://www.researchandmarkets.com/research/rs4wkl/china


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.